A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma (STREAM)
Uveal melanoma is the most common primary intra-ocular malignancy in adults with an incidence of 0.6 - 0.7 per 100,000 per year.
Prognosis of metastatic uveal melanoma is poor. In retrospective analyses a median survival time after detection of metastases of 5 months (Flaherty et al, 1998) and 7 months (Kath et al, 1993) was reported. For patients receiving no treatment reported median survival was 2.0 months compared with 5.2 months for those receiving treatment for metastases (Gragoudas et al, 1991).
Up to now there is no established treatment of metastatic uveal melanoma. Some therapeutic approaches with locoregional treatment or systemic chemotherapy have been undertaken:
In case of metastatic disease which is confined to the liver in about 85% of patients with uveal melanoma surgical resection led to a median survival of 14 months (Mariani et al, 2009) or 19 months and a 5-year survival rate of 22% in a selected patient population (Adam et al, 2006).
As locoregional treatment option treatment with fotemustine via direct intra-arterial hepatic infusion was investigated and led to a median survival of 15 months (Peters et al, 2006). This was not a randomized trial, but a report on 101 consecutive treated patients. Additional debulking surgery was performed whenever feasible.
A randomized phase III trial comparing intra-arterial hepatic fotemustine administration with intravenous systemic fotemustine and overall survival as primary endpoint is still ongoing (EORTC 18021).
Thus, no systemic chemotherapy is approved for metastatic uveal melanoma. Although no specific genes have been linked to the pathogenesis of uveal melanoma, preclinical studies suggest potential benefit of inhibitors of Bcl-2, ubiquitin-proteasome, histone deactylase, mitogen-activated protein kinase and phosphatidylinositol-3-kinase-AKT pathways, and receptor tyrosine kinases.
Thus, sorafenib as inhibitor of b-Raf and Raf-1 (c-Raf or c-Raf-1), pro-angiogenic vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR) may potentially lead to a benefit for patients with metastatic uveal melanoma in terms of disease control and prolongation of survival.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma|
- Progression Free Survival [ Time Frame: Every 8 weeks for 1 year ] [ Designated as safety issue: Yes ]
- Number of patients with adverse events [ Time Frame: Every 8 weeks for 1 year ] [ Designated as safety issue: Yes ]
- Overall Survival [ Time Frame: Every 8 weeks for 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||June 2011|
|Estimated Study Completion Date:||June 2017|
|Estimated Primary Completion Date:||June 2016 (Final data collection date for primary outcome measure)|
Experimental: Sorafenib blinded Phase
400 mg Sorafenib bid until PD
400 mg Sorafenib bid until PD if staging after Run-In was SD
Placebo Comparator: Placebo blinded Phase
Two tbl. in the morning and two tbl. in teh evening until PD
two tablets in the morning and two in the evening.
Experimental: Sorafenib Open Phase
400 mg Sorafenib bid until PD
400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01377025
|Contact: Max El Scheulen, Prof.||+49201723 ext firstname.lastname@example.org|
|Universitätsmedizin Berlin, Charité Campus Benjamin Franklin||Not yet recruiting|
|Berlin, Germany, 12203|
|Contact: Ulrich Keilholz, Prof.Dr.med. +30450513502 email@example.com|
|Principal Investigator: Ulrich Keilholz, Prof.Dr.med.|
|Sub-Investigator: Ronny Schuster, Dr. med.|
|Sub-Investigator: Verena Kümmerlen, Dr. med.|
|Sub-Investigator: Konrad Klinghammer, Dr. med.|
|Sub-Investigator: Anne Letsch, Dr. med.|
|Universitätsklinikum Erlangen||Not yet recruiting|
|Erlangen, Germany, 91052|
|Contact: Eckhart Kämpgen, Prof.Dr.med. +499131853 ext 3661 firstname.lastname@example.org|
|Principal Investigator: Eckhart Kämpgen, Prof.Dr.med.|
|Sub-Investigator: Michael Erdmann, Dr. med.|
|Sub-Investigator: Lisa Löhberg, Dr. med.|
|Sub-Investigator: Kerstin L. Gebhard-Schmauser, Dr. med.|
|Sub-Investigator: Cornelia Erfurt-Berge, Dr. med.|
|Sub-Investigator: Petra Keikavoussi, Dr. med.|
|Essen, Germany, 45147|
|Contact: Max. E. Scheulen, Prof.Dr.med. +49201723 ext 3152 email@example.com|
|Principal Investigator: Max E. Scheulen, Prof.Dr.med.|
|Sub-Investigator: Heike Richly, Dr. med.|
|Sub-Investigator: Andreas C. Hoffmann, Dr. med.|
|Principal Investigator:||Max E. Scheulen, Prof.||Universiätsklinikum Essen|